文献速递胸部肿瘤放疗

对侧食管保护IMRT可降低III期非小细胞肺癌根治性同步放化疗患者放射性食管炎的发生频率和严重程度且不增加边缘失败风险

Reduced frequency and severity of radiation esophagitis without marginal failure risk by contralateral esophagus sparing IMRT in stage III non-small cell lung cancer patients undergoing definitive concurrent chemoradiotherapy.
PubMed 文献 · Radiother Oncol · 2024-07-17

研究纳入2021年1月至2023年5月接受根治性同步放化疗的183例III期非小细胞肺癌患者,其中159例食管距内靶区1 cm以内。比较159例需对侧食管保护患者中实际应用对侧食管保护IMRT(41例)与未应用(118例)者的食管炎频率、严重程度及失败模式,发现应用者疼痛事件更少更轻,失败模式、无进展生存和总生存无差异。

要点

  • 对侧食管保护IMRT组止痛药使用率53.7% vs 未应用组77.1%(p=0.008)。
  • 对侧食管保护IMRT组AQA评分2-3分者39.0% vs 未应用组68.6%(p=0.002)。
  • 多因素分析中食管与PTV重叠体积HR=1.32(95%CI 1.12-1.55,p=0.001),对侧食管保护IMRT应用HR=0.31(95%CI 0.13-0.76,p=0.010)。

核心结论

  • 对侧食管保护IMRT应用可减少疼痛事件的发生频率和严重程度,且不损害肿瘤学结局。
  • 作者认为希望进一步开展 preferably 随机方式的研究。

研究设计与样本

  • 2021年1月至2023年5月,183例III期非小细胞肺癌患者接受根治性同步放化疗。
  • 159例食管距内靶区1 cm以内者为需对侧食管保护患者,其中实际应用对侧食管保护IMRT者41例,未应用者118例,应用与否由主管放射肿瘤科医生决定。
  • 所有患者接受根治性同步放化疗,放疗剂量66 Gy分30次,同步化疗。

主要发现

  • 对侧食管保护IMRT组止痛药使用率53.7% vs 未应用组77.1%(p=0.008)。
  • 对侧食管保护IMRT组AQA评分2-3分者39.0% vs 未应用组68.6%(p=0.002)。
  • 多因素分析中食管与计划靶区重叠体积HR=1.32(95%CI 1.12-1.55,p=0.001),对侧食管保护IMRT应用HR=0.31(95%CI 0.13-0.76,p=0.010),均与AQA评分2-3分发生频率相关。
  • 失败模式、无进展生存和总生存方面无差异。

局限性

  • 对侧食管保护IMRT的实际应用由主管放射肿瘤科医生决定。
  • 作者结论指出希望进一步开展 preferably 随机方式的研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation esophagitis is frequent and annoying toxicity in high dose thoracic radiation therapy. Contalateral esophagus sparing intensity modulated radiation therapy (CES-IMRT) has been proposed to mitigate this problem, and this is to report the impact of CES-IMRT in definitive concurrent chemoradiotherapy (dCCRT) for lung cancer patients. MATERIALS AND METHODS: From January 2021 till May 2023, 183 stage III non-small cell lung cancer patients underwent dCCRT. Esophagus was located within 1 cm from internal target volume in 159 patients. We comparatively evaluated the frequency and severity of esophagitis by pain-killer usage, analgesic quantification algorithm (AQA) score, and failure patterns in 159 CES-necessary patients. RESULTS: All patients underwent dCCRT (66 Gy in 30 fractions with concurrent chemotherapy). Actual CES-IMRT application was determined based on the discretion of responsible radiation oncologists: CES-applied in 41 patients; and CES-unapplied in 118. CES-applied patients experienced pain events less frequently (pain-killer usage: 53.7 % vs. 77.1 %, p = 0.008) and less severely (AQA score of 2-3: 39.0 % vs. 68.6 %, p = 0.002). On multivariate analyses, overlapping volume of esophagus and planning target (HR = 1.32, 95 % CI 1.12-1.55, p = 0.001) and CES-IMRT application (HR = 0.31, 95 % CI 0.13-0.76, p = 0.010) were associated with AQA score of 2-3 less frequently. There were no differences in failure pattern, progression-free survival, and overall survival. CONCLUSIONS: CES-IMRT application resulted in less frequent and less severe pain events without compromising oncologic outcomes. Further studies, preferably in a randomized fashion, would be desired.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Lim HS, Yang K, Noh JM, et al. Reduced frequency and severity of radiation esophagitis without marginal failure risk by contralateral esophagus sparing IMRT in stage III non-small cell lung cancer patients undergoing definitive concurrent chemoradiotherapy. Radiother Oncol. 2024. PMID: 39029592. doi:10.1016/j.radonc.2024.110436

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。